REG - Redx Pharma plc - Result of GM, Cancellation of Admission to Trading

Redx PharmaAnnouncement

19/04/2024 12:30

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240419:nRSS3673La&default-theme=true

RNS Number : 3673L  Redx Pharma plc  19 April 2024

REDX PHARMA PLC

 

("Redx" or the "Company")

 

Result of General Meeting and Cancellation of Admission to Trading on AIM

 

Alderley Park, UK, 19 April 2024 Redx (AIM:REDX), the clinical-stage
biotechnology company focused on discovering and developing novel, small
molecule, targeted therapeutics for the treatment of fibrotic disease and
cancer announces that, at the general meeting of the Company held earlier
today (the "General Meeting"), all resolutions put to the Company's
shareholders ("Shareholders") were duly passed on a poll.

 

The table below sets out the details of the votes put to Shareholders:

 

 Resolution Number                 Resolution Name                                                         Votes For                       Votes Against                     Votes Withheld*  Total Votes Cast (excl. withheld)

 (*indicates special resolution)
                                   No. of shares                                                                        % of shares voted  No. of shares  % of shares voted  No. of shares
 1*                                Cancellation Resolution                                                 351,522,100  99.75%             882,304        0.25%              4,291            352,404,404
 2*                                Re-registration Resolution and Adoption of New Articles of Association  351,522,100  99.75%             882,304        0.25%              4,291            352,404,404

 

*A vote withheld is not a vote in law and is not counted in the calculation of
the proportion of votes 'For' or 'Against'

 

The full text of the resolutions proposed and passed at the General Meeting
can be found in the circular containing, inter alia, the Notice of General
Meeting, which was published and posted to Shareholders on 2 April 2024 and is
available on the Company's website www.redxpharma.com
(http://www.redxpharma.com) (the "Circular").

 

AIM Delisting

 

Following approval by Shareholders at the General Meeting, the admission of
the ordinary shares of 1 pence each in the capital of the Company ("Ordinary
Shares") to trading on AIM will be cancelled (the "AIM Delisting"). The AIM
Delisting is expected to take place at 7:00 a.m. on 1 May 2024 and,
accordingly, the last day of dealings in Ordinary Shares on AIM is expected to
be 30 April 2024.

 

Matched Bargain Facility

 

It remains the Company's intention to provide a matched bargain facility to
assist Shareholders wishing to trade in Ordinary Shares following the AIM
Delisting. Further details with respect to the matched bargain facility, to be
provided by J P Jenkins, will be made available in due course on the Company's
website www.redxpharma.com (http://www.redxpharma.com) .

 

Capitalised terms used but not defined in this announcement shall have the
same meaning given to such terms in the Circular.

 

 For further information, please contact:
 Redx Pharma Plc                                T: +44 (0)1625 469 918

 UK Headquarters

 Caitlin Pearson, Head of Communications

 ir@redxpharma.com (mailto:ir@redxpharma.com)

 SPARK Advisory Partners (Nominated Adviser)    T: +44 (0)203 368 3550
 Matt Davis/Adam Dawes

 Panmure Gordon (UK) Limited (Broker)           T: +44 (0)207 886 2500
 Rupert Dearden/Freddy Crossley/Emma Earl

 FTI Consulting                                 T: +44 (0)203 727 1000
 Simon Conway/Ciara Martin

 

About Redx Pharma Plc

Redx Pharma (AIM: REDX) is a clinical-stage biotechnology company focused on
the discovery and development of novel, small molecule, targeted therapeutics
for the treatment of fibrotic disease, cancer and the emerging area of
cancer-associated fibrosis. Redx aims to progress its programmes to clinical
proof of concept before evaluating options for further development and
potential value creation. The Company expects a number of data points during
2024 including from lead fibrosis product candidate, the selective ROCK2
inhibitor, zelasudil (RXC007), in development for interstitial lung disease
and currently undertaking a Phase 2a trial for idiopathic pulmonary fibrosis
(IPF). The Company's second fibrosis candidate, RXC008, a GI-targeted ROCK
inhibitor for the treatment of fibrostenotic Crohn's disease, is in Phase 1
development and is expected to report healthy volunteer data; and Redx's lead
oncology product candidate, the Porcupine inhibitor zamaporvint (RXC004),
being developed as a targeted treatment for Wnt-ligand dependent cancers, is
expected to report anti-PD-1 combination Phase 2 data, following which Redx
will seek a partner for ongoing development.

 

The Company has a strong track record of discovering new drug candidates
through its core strengths in medicinal chemistry and translational science,
enabling the Company to discover and develop differentiated therapeutics
against biologically or clinically validated targets. The Company's
accomplishments are evidenced not only by its wholly-owned clinical-stage
product candidates and discovery pipeline, but also by its strategic
transactions, which includes the sale of pirtobrutinib (RXC005, LOXO-305), the
only non-covalent or reversible BTK inhibitor now approved by the US FDA, and
transactions with both AstraZeneca and Jazz Pharmaceuticals.

 

To subscribe to Email Alerts from Redx, please
visit: www.redxpharma.com/investor-centre/email-alerts/
(http://www.redxpharma.com/investor-centre/email-alerts/) .

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ROMFKLFFZZLFBBE